Q4 2025 Laboratorios Farmaceuticos ROVI SA Earnings Call Transcript
Key Points
- Laboratorios Farmaceuticos Rovi SA (STU:41L) reported a 4% increase in EBITDA, with the EBITDA margin expanding by 1.9 percentage points to 29.1% in 2025.
- The specialty pharmaceutical business saw an 11% increase in sales, driven by strong performance in the heparin division and products like OKEDI and Neparvis.
- The company announced a collaboration with Roche for the manufacture of a new medicine, reflecting strong momentum in new business and partnership expansion.
- Rovi acquired a manufacturing site in Phoenix, Arizona, enhancing its US-based manufacturing capabilities and adding high-potent cytotoxic capacities.
- The company advanced in artificial intelligence by acquiring a majority stake in Celis IA Technology, aiming to transform diagnostics in pathological anatomy.
- Total revenue in 2025 decreased by 1% compared to 2024, with operating revenue falling by 2%, mainly due to the performance of the CDMO business.
- Sales in the CMO business declined by 20%, primarily due to minimal revenue recognition related to Moderna vaccine production.
- The company expects a decline in heparin sales in 2026 due to aggressive pricing strategies from Chinese competitors and strong stock levels from partners.
- R&D expenses increased by 47% in 2025, driven by the completion of Phase 1 clinical trials and preparation for further development, impacting overall costs.
- The company anticipates significant R&D expenditure in 2026, potentially exceeding previous expectations, due to the start of patient recruitment for clinical trials.
Hello, everyone. This is Martha Campos, Head of Finance for ROVI.
Welcome to our company's review of business results for the full year 2025.
Before we begin, let me remind you that today's presentation and associated documentation are available on the investor relations section of Robi's website.
Please note that the information presented in this code contains a forward-looking statements based on our current beliefs and expectations.
Actual results could naturally differ due to known and unknown risks, uncertainties, and other factors, and we undertake no obligation to update or revi revi revise any of the statements.
Moving to today's agenda, Juan Lopez-Belmonte Encina, Rovi'sChairman and CEO.
We'll discuss on business performance for the full year 2025, as well as our outlook for 2026.
Javier López-Belmonte Encina, Rovi's Chief Financial Officer, will then review four-year financial results and provide an overview of our cash and debt position.
(Operator Instructions)
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
